StreetAlpha
13F holdings · Q3 2026

Sofinnova Investments

Menlo Park, CA · files as Sofinnova Investments, Inc.
Know the moment Sofinnova Investments filesYou follow Sofinnova Investments An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1631134

Sofinnova Investments reported 60 stocks worth $2B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are NTRA (31.6%), GMAB (7.7%) and JAZZ (4.8%). Compared with Q2 2026, the fund opened new positions in AZN, LLY and NVS, added to GMAB, JAZZ and AXSM, trimmed IMNM, IMTX and BMY and sold out of SUPN, GILD and COGT.

Latest filing: what Sofinnova Investments did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
16 new14 added19 trimmed9 sold outBought about $367M · sold about $291M
New 16
See all 16 →
Added 14
See all 14 →
Trimmed 19
See all 19 →
Sold out 9
See all 9 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$2B+8.3% vs last quarter · $2.3B including options
Stocks held6016 new · 9 sold out
Top 5 weight52.6%fairly concentrated
Turnover32%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
NTRA
Natera Inc
$641M31.6%1.6MNo change8 of 8
2
GMAB
Genmab A/s
$155M7.7%4.3M+304K (+8%)3 of 8
3
JAZZ
Jazz Pharmaceuticals PLC
$97.8M4.8%422K+57K (+16%)8 of 8
4
VERA
Vera Therapeutics Inc
$90.2M4.5%2.8MNo change8 of 8
5
AXSM
Axsome Therapeutics Inc
$82.2M4.1%446K+285K (+178%)8 of 8
6
SPTX
Seaport Therapeutics Inc
$71.9M3.5%3.6MNo change2 of 8
7
RAPP
Rapport Therapeutics Inc
$64M3.2%1.9MNo change8 of 8
8
AZN
Astrazeneca PLC Ord
$61.9M3.0%383KNew position2 of 8
9
AVBP
Arrivent Biopharma Inc
$51.4M2.5%1.7MNo change8 of 8
10
RYTM
Rhythm Pharmaceuticals Inc
$50.9M2.5%535K+127K (+31%)8 of 8
🔒 50 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
SUPN
Supernus Pharmaceuticals Inc
$48.2M1M
GILD
Gilead Sciences Inc
$43.3M343K
COGT
Cogent Biosciences Inc
$40.1M1M
ALC
Alcon AG
$17.2M256K
INSM
Insmed Inc
$16.9M158K

🔒 Free account: see all 9.

Options

valued at the underlying shares
StockTypeValueSharesChange
IWM
Ishares TR
Put$139M500K+500,000
QQQ
Invesco Qqq TR
Put$55.5M75K+75,000
BMY
Bristol Myers Squibb Co
Call$43.7M700K+700,000
IRON
Disc Medicine Inc
Put$13.1M200K+200,000
EWTX
Edgewise Therapeutics Inc
Put$12.2M300K+300,000

🔒 Free account: see all 7.

Reported value

last 8 quarters
$1.4BQ4 '24
$1.3BQ1 '25
$1.5BQ2 '25
$1.6BQ3 '25
$2.3BQ4 '25
$2BQ1 '26
$1.9BQ2 '26
$2BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Sofinnova Investments 13F FAQ

What does Sofinnova Investments own?

Sofinnova Investments reported 60 stocks worth $2B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are NTRA (31.6%), GMAB (7.7%) and JAZZ (4.8%). The table above lists every position in the filing (the top 10 without an account).

What did Sofinnova Investments buy and sell in Q3 2026?

Compared with Q2 2026: 16 new positions, 14 added to, 19 trimmed and 9 sold out. New positions include AZN, LLY and NVS. It sold all of SUPN, GILD and COGT.

When will Sofinnova Investments file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Sofinnova Investments's portfolio worth?

The Q3 2026 filing reports $2B in US stocks ($2.3B including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.